WCN26-3585 Retrospective Evaluation of Clinical and Economic Outcomes in Immune Thrombotic Thrombocytopenic Purpura Patients Treated With or Without Caplacizumab

Read full text Summarise with VIRAT
Authors: Seinosuke Horikawa, Takaya Handa, Masashi Nishikubo, Satoru Kurihara, Naoya Kamae, Fu Takata, Keisuke Osaki, Shusuke Hiragi, Yoshimitsu Shimomura, Ryusuke Yamamoto, Yuya Nagai, Nobuhiro Hiramoto
+3 more Noboru Yonetani, Tadakazu Kondo, Akihiro Yoshimoto
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Plasma exchange (PE) using fresh frozen plasma (FFP) is the first-line treatment for immune thrombotic thrombocytopenic purpura (iTTP). Caplacizumab (Cap), anti-von Willebrand Factor antibody, demonstrated early improvement in platelet function and reduced the incidence of PE (NEJM 2016;374:511-522). The 2023 TTP Clinical Practice Guidelines state that Cap is the first-line treatment for iTTP. iTTP is a rare disease, and the actual state of treatment in the real world and changes in healthcare costs before and after Cap have not yet been sufficiently reported.

Fields of Study & Subjects

Complement system in diseases Platelet Disorders and Treatments Blood transfusion and management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105671–105671
Publication date
25 March 2026
Language
EN